Saturday 23 April 2011

Chelsea Therapeutics and Droxidopa

Chelsea Therapeutics will seek federal approval for its blood pressure drug.
Northera is designed to treat neurogenic orthostatic hypotension, which is a drop in blood pressure. The product is Chelsea's lead drug candidate and the company does not yet have a product on the market.
Chelsea Therapeutics International Ltd. has previously said it hopes to launch the drug in early 2012. Meanwhile, the company will continue to study the drug as a potential treatment for neurogenic orthostatic hypotension from Parkinson's Disease.
The active ingredient in Northera is droxidopa and Chelsea is also studying droxidopa as a treatment for fibromyalgia, a chronic disease that causes muscle pain and fatigue.
http://www.businessweek.com/ap/financialnews/D9MM7E2G0.htm

No comments:

Post a Comment